Search research articles
Contact Us
Filters
Showing results (201-210 of 362) with videos related to
Page
of 37
Sort By:
JCO Global Oncology
|
April 6, 2021
OncoAlert Round Table Discussions: The Global COVID-19 Experience
Gilberto Morgan, Evandro de Azambuja, Kevin Punie, et al.
Cancer Nursing
|
September 10, 2021
Pilot Testing of a Nurse-Led Basic Symptom Self-management Support for Patients Receiving First-Line Systemic Outpatient Anticancer Treatment: A Cluster-Randomized Study (Symptom Navi Pilot Study)
Marika Bana, Karin Ribi, Solange Peters, et al.
Cancers
|
January 8, 2023
Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study
Carole Bandiera, Isabella Locatelli, Perrine Courlet, et al.
Revue Medicale Suisse
|
May 15, 2025
[Adverse effects of new therapeutic approaches in thoracic oncology]
Almaz Sammya, Clément Normand, Nicolas Desbaillets, et al.
Nature Reviews. Clinical Oncology
|
May 17, 2019
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Filipe Martins, Latifyan Sofiya, Gerasimos P Sykiotis, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 14, 2026
Domvanalimab combined with zimberelimab as first-line treatment in patients with PD-L1-high, advanced non-small cell lung cancer: Results from the randomized phase 2 ARC-10 study, Part1
Jarushka Naidoo, Solange Peters, Yotsawaj Runglodvatana, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 27, 2026
New biomarkers for antibody-drug conjugates in lung cancer the pathologist's perspective
Véronique Hofman, Guylène Rignol, Baharia Mograbi, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 6, 2012
VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528
Oliver Gautschi, Anne-Marie Dingemans, Susanne Crowe, et al.
JTO Clinical and Research Reports
|
October 13, 2025
Long-term Survival Analysis From PERLA, A Phase II Randomized Trial of Dostarlimab With Chemotherapy Versus Pembrolizumab With Chemotherapy in Metastatic Nonsquamous NSCLC
Sun Min Lim, Ana Laura Ortega Granados, Gustavo Dix Junqueira Pinto, et al.
JCO Global Oncology
|
August 7, 2020
Survey of the Impact of COVID-19 on Oncologists' Decision Making in Cancer
Yüksel Ürün, Syed A Hussain, Ziad Bakouny, et al.
Page
of 37
Search research articles
Search
Showing results (201-210 of 362) with videos related to
Sort By:
Page
of 37
JCO Global Oncology
|
April 6, 2021
OncoAlert Round Table Discussions: The Global COVID-19 Experience
Gilberto Morgan, Evandro de Azambuja, Kevin Punie, et al.
Cancer Nursing
|
September 10, 2021
Pilot Testing of a Nurse-Led Basic Symptom Self-management Support for Patients Receiving First-Line Systemic Outpatient Anticancer Treatment: A Cluster-Randomized Study (Symptom Navi Pilot Study)
Marika Bana, Karin Ribi, Solange Peters, et al.
Cancers
|
January 8, 2023
Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study
Carole Bandiera, Isabella Locatelli, Perrine Courlet, et al.
Revue Medicale Suisse
|
May 15, 2025
[Adverse effects of new therapeutic approaches in thoracic oncology]
Almaz Sammya, Clément Normand, Nicolas Desbaillets, et al.
Nature Reviews. Clinical Oncology
|
May 17, 2019
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Filipe Martins, Latifyan Sofiya, Gerasimos P Sykiotis, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 14, 2026
Domvanalimab combined with zimberelimab as first-line treatment in patients with PD-L1-high, advanced non-small cell lung cancer: Results from the randomized phase 2 ARC-10 study, Part1
Jarushka Naidoo, Solange Peters, Yotsawaj Runglodvatana, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 27, 2026
New biomarkers for antibody-drug conjugates in lung cancer the pathologist's perspective
Véronique Hofman, Guylène Rignol, Baharia Mograbi, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 6, 2012
VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528
Oliver Gautschi, Anne-Marie Dingemans, Susanne Crowe, et al.
JTO Clinical and Research Reports
|
October 13, 2025
Long-term Survival Analysis From PERLA, A Phase II Randomized Trial of Dostarlimab With Chemotherapy Versus Pembrolizumab With Chemotherapy in Metastatic Nonsquamous NSCLC
Sun Min Lim, Ana Laura Ortega Granados, Gustavo Dix Junqueira Pinto, et al.
JCO Global Oncology
|
August 7, 2020
Survey of the Impact of COVID-19 on Oncologists' Decision Making in Cancer
Yüksel Ürün, Syed A Hussain, Ziad Bakouny, et al.
Page
of 37